Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

References

• Nathan SD Hassoun PM Pulmonary hypertension due to lung disease and/or hypoxia Clin Chest Med 2013 34 4 695 705 24267299
   PubMed Web of Science ®Google Scholar
• Simonneau G Gatzoulis MA Adatia I Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 2013 62 Suppl 25 D34 D41 24355639
   PubMed Web of Science ®Google Scholar
• Nathan SD Noble PW Tuder RM Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots Am J Respir Crit Care Med 2007 175 9 875 880 17255562
   PubMed Web of Science ®Google Scholar
• Ley B Collard HR Epidemiology of idiopathic pulmonary fibrosis Clin Epidemiol 2013 5 483 492 24348069
   PubMedGoogle Scholar
• King C Nathan SD Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases Curr Opin Pulm Med 2013 19 5 466 473 23912191
   PubMed Web of Science ®Google Scholar
• Panos RJ Mortenson RL Niccoli SA King TE Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment Am J Med 1990 88 4 396 404 2183601
   PubMed Web of Science ®Google Scholar
• Nathan SD Shlobin OA Weir N Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium Chest 2011 140 1 221 229 21729893
   PubMed Web of Science ®Google Scholar
• Lettieri CJ Nathan SD Barnett SD Ahmad S Shorr AF Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis Chest 2006 129 3 746 752 16537877
   PubMed Web of Science ®Google Scholar
• Nadrous HF Pellikka PA Krowka MJ Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Chest 2005 128 4 2393 2399 16236900
   PubMed Web of Science ®Google Scholar
• Song JW Song JK Kim DS Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis Respir Med 2009 103 2 180 186 19097877
   PubMed Web of Science ®Google Scholar
• Sherner J Collen J King CS Nathan SD Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications Curr Respir Care Rep 2012 1 233 242
   Google Scholar
• Nathan SD Shlobin OA Ahmad S Urbanek S Barnett SD Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis Chest 2007 131 3 657 663 17356077
   PubMed Web of Science ®Google Scholar
• Zisman DA Karlamangla AS Ross DJ High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis Chest 2007 132 3 773 779 17573485
   PubMed Web of Science ®Google Scholar
• Krowka MJ Ahmad S de Andrade JA A Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis [abstract] Chest 2007 132 4 MeetingAbstracts 633a 633
   Web of Science ®Google Scholar
• Zisman DA Schwarz M Anstrom KJ Collard HR Flaherty KR Hunninghake GW Idiopathic Pulmonary Fibrosis Clinical Research Network A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis N Engl J Med 2010 363 7 620 628 20484178
   PubMed Web of Science ®Google Scholar
• Ghofrani HA Wiedemann R Rose F Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial Lancet 2002 360 9337 895 900 12354470
   PubMed Web of Science ®Google Scholar
• Collard HR Anstrom KJ Schwarz MI Zisman DA Sildenafil improves walk distance in idiopathic pulmonary fibrosis Chest 2007 131 3 897 899 17356110
   PubMed Web of Science ®Google Scholar
• Günther A Enke B Markart P Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study Eur Respir J 2007 29 4 713 719 17215312
   PubMed Web of Science ®Google Scholar
• Jackson RM Glassberg MK Ramos CF Bejarano PA Butrous G Gómez-Marín O Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis Lung 2010 188 2 115 123 20012639
   PubMed Web of Science ®Google Scholar
• King TE Behr J Brown KK BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2008 177 1 75 81 17901413
   PubMed Web of Science ®Google Scholar
• Raghu G Behr J Brown KK ARTEMIS-IPF Investigators* Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial Ann Intern Med 2013 158 9 641 649 23648946
   PubMed Web of Science ®Google Scholar
• Raghu G Million-Rousseau R Morganti A Perchenet L Behr J MUSIC Study Group Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Eur Respir J 2013 42 6 1622 1632 23682110
   PubMed Web of Science ®Google Scholar
• Han MK Bach DS Hagan PG IPFnet Investigators Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction Chest 2013 143 6 1699 1708 23732584
   PubMed Web of Science ®Google Scholar
• Seeger W Adir Y Barberà JA Pulmonary hypertension in chronic lung diseases J Am Coll Cardiol 2013 62 25 Suppl D D109 D116 24355635
   PubMed Web of Science ®Google Scholar
• Nathan SD Shlobin OA Barnett SD Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis Respir Med 2008 102 9 1305 1310 18619825
   PubMed Web of Science ®Google Scholar
• Chin KM Kim NH Rubin LJ The right ventricle in pulmonary hypertension Coron Artery Dis 2005 16 1 13 18 15654194
   PubMed Web of Science ®Google Scholar
• Haddad F Doyle R Murphy DJ Hunt SA Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure Circulation 2008 117 13 1717 1731 18378625
   PubMed Web of Science ®Google Scholar
• Saggar R Khanna D Vaidya A Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis Thorax 2014 69 2 123 129 24431095
   PubMed Web of Science ®Google Scholar
• Hamada K Nagai S Tanaka S Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis Chest 2007 131 3 650 656 17317730
   PubMed Web of Science ®Google Scholar
• Nathan SD Shlobin OA Ahmad S Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis Respiration 2008 76 3 288 294 18216461
   PubMed Web of Science ®Google Scholar
• Wagner PD The multiple inert gas elimination technique (MIGET) Intensive Care Med 2008 34 6 994 1001 18421437
   PubMed Web of Science ®Google Scholar
• Snow JL Kawut SM Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy Clin Chest Med 2007 28 1 75 viii 17338929
   PubMed Web of Science ®Google Scholar
• Albera C Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Eur Respir Rev 2011 20 121 195 200 21881147
   PubMedGoogle Scholar
• Farber HW Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Circulation 2012 126 3 258 260 22696078
   PubMed Web of Science ®Google Scholar
• Gabler NB French B Strom BL Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials Circulation 2012 126 3 349 356 22696079
   PubMed Web of Science ®Google Scholar
• Savarese G Paolillo S Costanzo P Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials J Am Coll Cardiol 2012 60 13 1192 1201 22995024
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M Bull TM Saggar R New trial designs and potential therapies for pulmonary artery hypertension J Am Coll Cardiol 2013 62 Suppl 25 D82 D91 24355645
   PubMed Web of Science ®Google Scholar
• Dolmage TE Hill K Evans RA Goldstein RS Has my patient responded? Interpreting clinical measurements such as the 6-minute-walk test Am J Respir Crit Care Med 2011 184 6 642 646 21680947
   PubMed Web of Science ®Google Scholar
• ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 2002 166 1 111 117 12091180
   PubMed Web of Science ®Google Scholar
• Lama VN Flaherty KR Toews GB Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia Am J Respir Crit Care Med 2003 168 9 1084 1090 12917227
   PubMed Web of Science ®Google Scholar
• Lettieri CJ Nathan SD Browning RF Barnett SD Ahmad S Shorr AF The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis Respir Med 2006 100 10 1734 1741 16545950
   PubMed Web of Science ®Google Scholar
• Swigris JJ Wamboldt FS Behr J The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference Thorax 2010 65 2 173 177 19996335
   PubMed Web of Science ®Google Scholar
• Swigris JJ Swick J Wamboldt FS Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis Chest 2009 136 3 841 848 19395579
   PubMed Web of Science ®Google Scholar
• Swigris JJ Olson AL Shlobin OA Ahmad S Brown KK Nathan SD Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis Respirology 2011 16 3 439 445 20946337
   PubMed Web of Science ®Google Scholar
• Weir NA Brown AW Shlobin OA The influence of alternative instruction on 6-min walk test distance Chest 2013 144 6 1900 1905 23975232
   PubMed Web of Science ®Google Scholar
• Swigris JJ Fairclough D Patient-reported outcomes in idiopathic pulmonary fibrosis research Chest 2012 142 2 291 297 22871754
   PubMed Web of Science ®Google Scholar
• Yorke J Jones PW Swigris JJ Development and validity testing of an IPF-specific version of the St George’s Respiratory Questionnaire Thorax 2010 65 10 921 926 20861296
   PubMed Web of Science ®Google Scholar
• Swigris JJ Wilson SR Green KE Sprunger DB Brown KK Wamboldt FS Development of the ATAQ-IPF: a tool to assess quality of life in IPF Health Qual Life Outcomes 2010 8 77 20673370
   PubMed Web of Science ®Google Scholar
• Noth I Anstrom KJ Calvert SB Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2012 186 1 88 95 22561965
   PubMed Web of Science ®Google Scholar
• Pulido T Adzerikho I Channick RN SERAPHIN Investigators Macitentan and morbidity and mortality in pulmonary arterial hypertension N Engl J Med 2013 369 9 809 818 23984728
   PubMed Web of Science ®Google Scholar
• Raghu G Collard HR Anstrom KJ Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials Am J Respir Crit Care Med 2012 185 10 1044 1048 22505745
   PubMed Web of Science ®Google Scholar
• Taichman DB McGoon MD Harhay MO Wide variation in clinicians’ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension Mayo Clin Proc 2009 84 7 586 592 19567712
   PubMed Web of Science ®Google Scholar
• King TE Albera C Bradford WZ All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials Am J Respir Crit Care Med 2014 189 7 825 831 24476390
   PubMed Web of Science ®Google Scholar
• Kaul S Diamond GA Trial and error. How to avoid commonly encountered limitations of published clinical trials J Am Coll Cardiol 2010 55 5 415 427 20117454
   PubMed Web of Science ®Google Scholar
• Minai OA Sahoo D Chapman JT Mehta AC Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease Respir Med 2008 102 7 1015 1020 18343648
   PubMed Web of Science ®Google Scholar
• Raghu G King TEJr Behr J Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1) Eur Respir J 2010 35 1 118 123 19679600
   PubMed Web of Science ®Google Scholar
• King TE Brown KK Raghu G BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 184 1 92 99 21474646
   PubMed Web of Science ®Google Scholar